Montelukast Eurogenerics

Montelukast, the active ingredient in Montelukast Eurogenerics, is a leukotriene receptor antagonist presented as a tablet for oral use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as prescribed by a healthcare professional.

GNH USA supplies Montelukast Eurogenerics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to reduce airway inflammation and bronchoconstriction.

- Asthma: improves control of chronic asthma and reduces frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching caused by seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Upper respiratory tract infection: symptoms of cold or flu. - Abdominal pain: discomfort in the stomach area. - Cough: persistent dry cough. - Diarrhoea: loose stools. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Mood changes: depression, anxiety, or suicidal thoughts. - Allergic reactions: hives, swelling, or difficulty breathing. - Liver enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin blistering. - Angio‑edema: rapid swelling of face, lips, or tongue. - Anaphylaxis: life‑threatening systemic allergic response.

Montelukast should be used with consideration of the following precautions.

- Pregnancy: consult a healthcare provider; safety data are limited. - Breastfeeding: discuss risks and benefits with a clinician. - Hepatic impairment: monitor liver function in patients with liver disease. - Psychiatric disorders: observe for mood changes or suicidal ideation. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; monitoring is advised.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: can decrease therapeutic effect by inducing metabolism.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): potential additive psychiatric effects. - Warfarin: occasional reports of altered INR; monitor coagulation. - Other leukotriene modifiers: no added benefit and increased risk of side effects. - CYP3A4 inhibitors (ketoconazole, erythromycin): may increase montelukast levels. - CYP2C9 inhibitors (fluconazole): possible modest increase in exposure.